Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Somaratne · SciRah

Researcher profile · Semantic Scholar

R. Somaratne

Share profile

R. Somaratne — researcher profile on SciRah

h-index: 35
Works: 103
Citations: 8,882

Most-cited papers

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
M. Sabatine, R. Giugliano, S. Wiviott, F. Raal +9 more
2015New England Journal of Medicine1,149 citations Open access
Semantic Scholar
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
S. Nicholls, R. Puri, T. Anderson, C. Ballantyne +15 more
2016Journal of the American Medical Association (JAMA)1,098 citations Open access
Semantic Scholar
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
F. Raal, Evan A. Stein, R. Dufour, T. Turner +14 more
2015The Lancet670 citations
Semantic Scholar
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca, P. Nault, R. Giugliano, A. Keech +11 more
2017Circulation626 citations Open access
Semantic Scholar
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
R. Giugliano, T. Pedersen, Jeong-Gun Park, G. D. de Ferrari +15 more
2017The Lancet590 citations Open access
Semantic Scholar
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
J. Robinson, B. Nedergaard, W. Rogers, Jonathan Fialkow +8 more
2014Journal of the American Medical Association (JAMA)514 citations
Semantic Scholar
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
S. Nissen, E. Stroes, Ricardo E. Dent-Acosta, R. Rosenson +14 more
2016Journal of the American Medical Association (JAMA)495 citations Open access
Semantic Scholar
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial
M. Koren, R. Giugliano, F. Raal, D. Sullivan +9 more
2014Circulation223 citations Open access
Semantic Scholar
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]
F. Raal, R. Giugliano, M. Sabatine, M. Koren +13 more
2016Journal of Lipid Research201 citations Open access
Semantic Scholar
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
G. Hirschfield, O. Chazouilleres, J. Drenth, D. Thorburn +14 more
2019Journal of Hepatology162 citations Open access
Semantic Scholar
Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
M. Koren, M. Sabatine, R. Giugliano, G. Langslet +6 more
2017JAMA cardiology161 citations Open access
Semantic Scholar
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
G. Fonarow, A. Keech, T. Pedersen, R. Giugliano +7 more
2017JAMA cardiology146 citations Open access
Semantic Scholar
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
G. Watts, D. Chan, R. Somaratne, S. Wasserman +3 more
2018European Heart Journal137 citations Open access
Semantic Scholar
Effect of Evolocumab on Coronary Plaque Composition.
S. Nicholls, R. Puri, T. Anderson, C. Ballantyne +14 more
2018Journal of the American College of Cardiology136 citations Open access
Semantic Scholar
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
N. Sattar, D. Preiss, J. Robinson, C. Stephen Djedjos +4 more
2016The Lancet Diabetes and Endocrinology132 citations Open access
Semantic Scholar
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
E. Stein, R. Giugliano, M. Koren, F. Raal +11 more
2014European Heart Journal132 citations
Semantic Scholar
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
S. Kasichayanula, A. Grover, M. Emery, M. Gibbs +3 more
2018Clinical Pharmacokinetics120 citations Open access
Semantic Scholar
Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
S. Gandra, G. Villa, G. Fonarow, M. Lothgren +3 more
2016Clinical Cardiology90 citations Open access
Semantic Scholar
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
S. Anker, S. Schroeder, D. Atar, Jeroen J. Bax +28 more
2016European Journal of Heart Failure90 citations Open access
Semantic Scholar
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts, D. Chan, R. Dent, R. Somaratne +4 more
2017Circulation88 citations Open access
Semantic Scholar
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
Robert P. Giugliano, A. Keech, S. Murphy, K. Huber +8 more
2017JAMA cardiology88 citations Open access
Semantic Scholar
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
P. Toth, O. Descamps, J. Genest, N. Sattar +8 more
2017Circulation70 citations Open access
Semantic Scholar
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
R. Rosenson, M. Daviglus, Y. Handelsman, P. Pozzilli +5 more
2019Diabetologia66 citations Open access
Semantic Scholar
Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
M. Shapiro, J. Minnier, H. Tavori, H. Kassahun +3 more
2019Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease60 citations Open access
Semantic Scholar
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
R. Puri, S. Nissen, R. Somaratne, L. Cho +10 more
2016American Heart Journal58 citations
Semantic Scholar
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
S. Nicholls, S. Nissen, F. Prati, S. Windecker +10 more
2021Cardiovascular Diagnosis and Therapy54 citations Open access
Semantic Scholar
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody in
N. Desai, R. Giugliano, Jing Zhou, P. Kohli +6 more
2014Journal of the American College of Cardiology50 citations Open access
Semantic Scholar
Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events.
J. Larosa, T. Pedersen, R. Somaratne, S. Wasserman
2013American Journal of Cardiology49 citations
Semantic Scholar
Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
P. Kohli, Nihar R. Desai, Robert P. Giugliano, Jae B. Kim +8 more
2012Clinical Cardiology47 citations Open access
Semantic Scholar
Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
J. Gibbs, S. Doshi, M. Kuchimanchi, A. Grover +6 more
2016Journal of clinical pharmacology42 citations Open access
Semantic Scholar
Effect of Evolocumab on Lipoprotein Particles.
P. Toth, N. Sattar, D. Blom, S. Martin +6 more
2017American Journal of Cardiology39 citations
Semantic Scholar
PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study
M. Mefford, R. Rosenson, M. Cushman, M. Farkouh +9 more
2017Circulation38 citations Open access
Semantic Scholar
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
N. Sattar, P. Toth, D. Blom, M. Koren +6 more
2017American Journal of Cardiology36 citations
Semantic Scholar
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
D. Gaudet, G. Langslet, S. Gidding, I. Luirink +6 more
2018Journal of Clinical Lipidology27 citations Open access
Semantic Scholar
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
D. Chan, G. Watts, R. Somaratne, S. Wasserman +2 more
2018Arteriosclerosis, Thrombosis and Vascular Biology27 citations Open access
Semantic Scholar
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
R. Dent, Raju Joshi, C. Stephen Djedjos, Jason C. Legg +6 more
2016SpringerPlus25 citations Open access
Semantic Scholar
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies
L. Cho, R. Dent, E. Stroes, E. Stein +5 more
2018Cardiovascular Drugs and Therapy23 citations
Semantic Scholar
Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial
M. O'Donoghue, R. Giugliano, A. Keech, Estella Kanevsky +6 more
2018Atherosclerosis21 citations
Semantic Scholar
Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
S. Baum, T. Sampietro, D. Datta, P. Moriarty +5 more
2019Journal of Clinical Lipidology19 citations Open access
Semantic Scholar
Effect of NGM 282 , a FGF 19 analogue , in Primary Sclerosing Cholangitis : a Multicentre , Randomized , Double-Blind , Placebo-Controlled Phase 2 Trial
G. Hirschfield, O. Chazouilleres, J. Drenth, Douglas +17 more
201818 citations
Semantic Scholar
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial
A. Lorenzatti, F. Eliaschewitz, Yun-Dai Chen, Jonathan Fialkow +6 more
2018Clinical Cardiology17 citations Open access
Semantic Scholar
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.
T. Brown, V. Bittner, Lisandro D. Colantonio, L. Deng +9 more
2020Journal of Clinical Lipidology16 citations
Semantic Scholar
Evolocumab: Considerations for the Management of Hyperlipidemia
B. S. Wiggins, Jeffrey Senfield, H. Kassahun, Armando Lira +1 more
2018Current Atherosclerosis Reports16 citations
Semantic Scholar
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
Edward Lee, J. Gibbs, M. Emery, G. Block +6 more
2019Clinical pharmacology in drug development15 citations Open access
Semantic Scholar
Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy
J. Robinson, W. Rogers, Bettina S. Nedergaard, Jonathan Fialkow +8 more
2014Clinical Cardiology15 citations Open access
Semantic Scholar
Effect of evolocumab on cholesterol synthesis and absorption[S]
M. Peach, Ren Y. Xu, Dan Fitzpatrick, L. Hamilton +4 more
2016Journal of Lipid Research13 citations Open access
Semantic Scholar
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals
S. Wasserman, M. Sabatine, M. Koren, R. Giugliano +6 more
2018Journal of Cardiovascular Pharmacology and Therapeutics11 citations
Semantic Scholar
Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
M. Kuchimanchi, A. Grover, M. Emery, R. Somaratne +3 more
2018Journal of Pharmacokinetics and Pharmacodynamics11 citations Open access
Semantic Scholar
LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES
M. Koren, R. Rosenson, B. Khan, N. Honarpour +4 more
201511 citations Open access
Semantic Scholar
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, D. Sullivan +6 more
2020Cardiology and Therapy9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Wasserman×27
Invite
S. Wasserman — researcher profile on SciRah
R. Scott×16
Invite
R. Scott — researcher profile on SciRah
M. Sabatine×11
Invite
M. Sabatine — researcher profile on SciRah
R. Giugliano×11
Invite
R. Giugliano — researcher profile on SciRah

×8

Invite

M. Koren — researcher profile on SciRah

Invite

F. Raal — researcher profile on SciRah

Invite

H. Kassahun — researcher profile on SciRah

Invite

R. Rosenson — researcher profile on SciRah

Invite

M. Elliott — researcher profile on SciRah

C. Ballantyne×5

Invite

C. Ballantyne — researcher profile on SciRah

Jason C. Legg×5

Invite

Jason C. Legg — researcher profile on SciRah

Invite

E. Stein — researcher profile on SciRah